BioSpace News Archive

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer.

AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease Anticipates initiating registration trial with kidney biopsy endpoint in mid-2022 to support potential full approval of AVR-RD-01 as first-line therapy, subject to FDA discussion and agreement Two additional patients dosed in last two months in ongoing FAB-GT Phase 2 trial; plan to enroll a total of up to 14 participants

AU-011 Demonstrates Targeted Cytotoxicity In Vitro and In Vivo in Both Breast and Lung Tumors, Demonstrating the Potential to Treat Human Choroidal Metastases Tumor Distribution of AU-011 in the Treatment of Choroidal Melanoma Also Presented Using Intravitreal and Suprachoroidal Administration

Gene editing or genome editing is the targeted insertion or modification of cells in living organism or cells and the method has come to occupy a crucial part of biomedical researches, constantly transforming various disciplines of life sciences.

The global depression devices market is foreseen to gain lucrative avenues during the forecast period of 2020 to 2030. One of the key reasons supporting the market growth is increased efforts of vendors to provide advanced care for patients dealing with issues related to mental health.

DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A., a clinical-stage biopharmaceutical company, reported financial results for the first quarter of 2021.

Lille, France; Cambridge, MA;May 3, 2021 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced the launch of NASHnext®, a novel, noninvasive diagnostic test for nonalcoholic steatohepatitis.

Ms. O’Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease

Professor Tsukasa Kumai, member of the Japan’s Olympic Committee Medical and Scientific Staff, will lead RepliCel’s Tendon Regeneration Clinical Testing in Japan

Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021